Eisai and Biogen report rising Leqembi use across key markets, highlighting growing clinical adoption of disease-modifying therapy for early Alzheimer’s disease.
Written By: Pharmacally Medical News Desk
Eisai Co., Ltd. and Biogen Inc. continue to report growing real-world use of Leqembi (lecanemab), an anti-amyloid beta protofibril antibody approved for patients with early Alzheimer’s disease, reflecting broader clinical adoption across major markets.
According to Eisai, cumulative global revenue for Leqembi reached JPY 61.8 billion for the period from April 1 to December 31, driven by increasing use in the United States, Japan, and China
Biogen’s latest earnings release provides a complementary view from the collaboration, reporting approximately USD 134 million in global in-market Leqembi sales during the fourth quarter, including around USD 78 million from the U.S., representing continued sequential growth and a 54% year-over-year increase.
Regional Trends Reflect Growing Clinical Confidence
Eisai’s regional breakdown highlights where clinical uptake is strongest. The United States remains the largest contributor, with JPY 31.2 billion, reflecting expanded use in patients with confirmed amyloid pathology and early symptomatic disease.
In Japan, Leqembi generated JPY 17.9 billion, supported by structured diagnostic pathways and post-marketing safety monitoring. China contributed JPY 8.3 billion indicating early but accelerating adoption in a large Alzheimer’s population.
Clinical Context Behind the Numbers
Leqembi targets soluble amyloid-beta protofibrils, a neurotoxic form associated with disease progression in Alzheimer’s disease. Clinical studies have shown that lecanemab can slow cognitive and functional decline in patients at the early stage of disease, shifting treatment goals from symptomatic relief toward disease modification.
The consistent growth reported by both Eisai and Biogen suggests increasing physician confidence in patient selection, amyloid confirmation strategies, and real-world management of safety considerations such as amyloid-related imaging abnormalities (ARIA).
Looking Ahead in Alzheimer’s Care
Eisai leads global development and regulatory strategy for lecanemab, with Eisai and Biogen jointly supporting commercialization and clinical education efforts. As experience with Leqembi expands in routine practice and additional formulations such as subcutaneous options progress through regulatory review, its uptake is expected to further shape the evolving treatment landscape for early Alzheimer’s disease.
Note: Revenue figures are presented in Japanese yen as reported by Eisai and in U.S. dollars as reported by Biogen.
References
Revenue of LEQEMBI® (Preliminary Basis), 06 February 2026, https://www.eisai.com/news/2026/news202607.html
Biogen Reports Fourth Quarter and Full Year 2025 Results, 06 February 2026, https://investors.biogen.com/static-files/cfad0ddd-0fdc-40d1-8da6-8c3dcaedd05b